Know HBV vs AGA MASH App

The chronic hepatitis B Treatment Decision Tool for Adults is developed by the Asian Liver Center at Stanford University in response to the WHO Global Health Sector Strategy on Viral Hepatitis to increase treatment rates when indicated to at least 80% by 2030. The app is an educational tool intended for primary healthcare professionals particularly in resource-limited countries as a general guide in the monitoring of HBsAg positive adults, and when antiviral treatment would be recommended based on the guidelines adapted from the World Health Organization or from the American Association for the Study of Liver Diseases. This app provides general guidance to primary healthcare professionals and is not a substitute for the advice provided by specialists in the management of liver disease and chronic hepatitis. Any course of action recommended or suggested in this educational tool should not be undertaken by the healthcare professional without an evaluation of the patient’s condition and contraindications. The patient should be provided with information about hepatitis B facts, and the potential benefits and risks of antiviral treatment. The app is not intended for use by non-healthcare professionals or patients. Non-healthcare professionals or patients must seek a doctor’s advice in addition to using this app before making any medical decisions.

American Gastroenterological Association’s MASH Clinical Care Pathway app is for use in any setting where health care professionals care for patients with MASH / MASLD, including primary care, endocrine, obesity medicine and gastroenterology practices. Developed with support by independent medical education grants from Intercept Pharmaceuticals, Inc., Pfizer Inc., Allergan, and Genfit. For more information visit gastro.org.